|Day Low/High||19.04 / 19.39|
|52 Wk Low/High||13.42 / 25.31|
These two firms have successful drugs and could make nice additions for larger companies.
Ironically, some experts now see biotech as a safe haven as the sector remains unaffected by trade wars and other global headwinds.
Two companies in pet pharmaceuticals plan to combine, while two other concerns are worth a look based on developments in their respective spaces.
Buy-write strategies give you confidence to 'buy the dip' while also adding an extra income stream.
One big change over the last few years has been the struggle of small concerns to penetrate mass markets even with approved and superior drugs.
Acquisition deals for biotech companies at the start of 2019 are giving the sector a nice boost; here are other names that could be merger candidates.
Investors are already more focused on what lies ahead when Q1 results start in early April.
It's probably no surprise that my picks for 2019 come from the biotech/biopharma space.
It seemed just a matter of time before M&A returned to the biotech industry with a vengeance.
Exelixis Inc., ANI Pharmaceuticals and Supernus Pharmaceuticals should not need to raise more capital in the foreseeable future.
Biotech ETFs could mitigate risk amid the sector's volatility, and names such as Exelixis, ANI Pharmaceuticals and Progenics hold promise.
I continue to deploy 'dry powder' into the biotech sector on dips using Buy-Write option strategies.
Exelixis Inc. and Aratana Therapeutics in particular surge after posting solid results Thursday.
These are just a few of the names I expect to do well to close out 2018.
These are a few of the names I expect to do well to close out 2018.
The credit card provider and the biotech concern appear cheap relative to their potential.
Your burning biotech questions answered in our latest mailbag.
We'll answer two of the common questions we have received so far in March.
The South San Francisco, Calif.-based company said Oct. 16 its Phase 3 study of cabozantinib achieved its primary endpoint of overall survival in patients that have advanced hepatocellular carcinoma.
The market is pretty close to where it was during our last update at noon EST. So far it has been a nicely green day across the board. Oncology mid-cap concern Tesaro is not giving up its big takeover speculation rise yesterday and is up another 3%...
Technical indicators indicate the markets are not extended and have consolidated nicely.
Animal health and oncology deal activity is heating up in 2017.
I'm feeling pressure to force some trades today, but I'm trying to stay selective.